. 2015 Oct 21;21(39):11127–11140. doi: 10.3748/wjg.v21.i39.11127

Table 1.

Demographic features and clinicopathologic correlation of fibulin-5 in patients with hepatocellular carcinoma

Parameter		Total No. of patients (n = 140)	FBLN-5 expression		P value¹
Parameter		Total No. of patients (n = 140)	High (n= 93)	Low (n = 47)
Age (yr)	< 50	54	40	14	P value¹	0.211
Age (yr)	≥ 50	86	55	31		0.211
Gender	Male	113	79	34	0.287
Gender	Female	27	16	11	0.287
Tumor size (cm)	< 5	82	57	25	0.618
Tumor size (cm)	≥ 5	58	38	20	0.618
No. of tumor nodules	1	122	87	35	0.023²
No. of tumor nodules	≥ 2	18	8	10	0.023²
Recurrent Cancer	Absent	87	64	23	0.064
Recurrent Cancer	Present	53	31	22	0.064
Cirrhosis	Absent	50	29	21	0.063
Cirrhosis	Present	90	66	24	0.063
Serum AFP level	Negative	79	52	27	0.558
Serum AFP level	Positive	61	43	18	0.558
HBV	HBsAg (-)	32	22	10	0.902
HBV	HBsAg (+)	108	73	35	0.902
TNM tumor stage	I + II	102	79	23	0.001²
TNM tumor stage	III + IV	38	16	22	0.001²
BCLC tumor stage	0 + A	93	74	19	0.001²
BCLC tumor stage	B + C + D	47	21	26	0.001²

P value from χ² or Fisher exact test;

Statistically significant. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; AFP: Alpha-fetoprotein; TNM: Tumor-node-metastasis; HBsAg: Hepatitis B surface antigen; FBLN-5: Fibulin-5; BCLC: Barcelona clinic liver cancer.